Santaris Pharma A/S is a privately held clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies. The Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine developed by Santaris Pharma A/S combine the Company’s proprietary LNA chemistry with its highly specialized and targeted drug development capabilities to rapidly deliver potent single-stranded LNA-based drug candidates across a multitude of disease states. The Company’s research and development activities focus on infectious diseases and metabolic disorders, while partnerships with major pharmaceutical companies include a range of therapeutic areas including cancer, cardiovascular disease, infectious and inflammatory diseases, and rare genetic disorders. The Company has strategic partnerships with miRagen Therapeutics, Shire plc, Pfizer, GlaxoSmithKline, Enzon Pharmaceuticals, RaNa and Bristol-Myers Squibb.
Santaris Pharma A/S, founded in 2003, is headquartered in Denmark with operations in the United States.
If you are interested in job opportunities and would like to play a role in an exciting company with an enormous potential, please send a job application to firstname.lastname@example.org or to:
Santaris Pharma A/S
c/o Bo Ritsmar
Corporate Project & HSE manager
DK 2970 Hørsholm